

In the Claims:

Please amend the claims according to the claim list provided below.

1-43. (cancelled).

44. (previously presented) A composition comprising a nucleic acid and at least two fatty acids or pharmaceutically acceptable salts thereof, wherein said nucleic acid has a cytosine to 5-methyl-cytosine substitution; a 2'-methoxyethoxy modification; a phosphorothioate linkage and a cytosine to 5-methyl-cytosine substitution; or a phosphorothioate linkage and a 2'-methoxyethoxy modification.

45. (previously presented) The composition of claim 44 wherein said nucleic acid is an oligonucleotide.

46. (previously presented) The composition of claim 44 wherein each fatty acid is, independently, arachidonic acid, oleic acid, lauric acid, caprylic acid, capric, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprinate, tricaprinate, monoolein, dilaurin, glyceryl 1-monocaprinate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof.

47. (previously presented) The composition of claim 44 further comprising at least one carrier compound.

48. (previously presented) The composition of claim 47 wherein said carrier compound is selected from the group consisting of polyinosinic acid, dextran sulfate, polycytidylic acid and 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid.

49. (previously presented) The composition of claim 45 wherein said oligonucleotide is

an antisense oligonucleotide.

50. (previously presented) The composition of claim 49 wherein said antisense oligonucleotide decreases the expression of a cellular adhesion protein or the rate of cellular proliferation.

51-52. (cancelled)

53. (previously presented) The composition of claim 44 wherein said composition is water based.

54. (previously presented) The composition of claim 44 wherein said composition is propylene glycol based.

55. (previously presented) The composition of claim 44 wherein said composition comprises less than about 8% water.

56. (cancelled)

57. (previously presented) The composition of claim 46 wherein one of said fatty acids is lauric acid and the other of said fatty acids is capric acid.

58. (previously presented) The composition of claim 44 further comprising a bile salt.

59. (previously presented) The composition of claim 58 wherein said bile salt is cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate, sodium glycodihydrofusidate, polyoxyethylene-9-lauryl ether or a pharmaceutically acceptable

salt thereof.

60. (previously presented) The composition of claim 45 wherein said oligonucleotide is in prodrug form.

61. (currently amended) A composition comprising a nucleic acid and capric acid and ~~or~~ lauric acid, or a pharmaceutically acceptable salt thereof, wherein said nucleic acid has a modified nucleobase or a modified sugar residue.

62. (previously presented) The composition of claim 61 wherein said nucleic acid is an antisense oligonucleotide.

63. (previously presented) The composition of claim 62 wherein said antisense oligonucleotide decreases the expression of a cellular adhesion protein or the rate of cellular proliferation.

64. (previously presented) The composition of claim 61 wherein said nucleic acid has a cytosine to 5-methyl-cytosine substitution or a 2'-methoxyethoxy modification.

66-91. (canceled).